Mon, Mar
48 New Articles

B2RLaw Advises Proteon Pharmaceuticals on Strategic Partnership with Skretting

B2RLaw Advises Proteon Pharmaceuticals on Strategic Partnership with Skretting

  • Smaller Small Medium Big Bigger
  • Default Helvetica Segoe Georgia Times

B2RLaw has advised Proteon Pharmaceuticals on a strategic partnership with Skretting aimed at tackling challenges in the aquaculture industry.

Proteon Pharmaceuticals is a Polish biotech company with a vision to develop natural feed additives that help remove antibiotics from the food chain and improve animal and human health. The company uses precision biology for micro-biome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

Norway-based Skretting is the world’s largest producer of feeds for farmed fish. The company has operations on five continents and produces 2.5 million tons of feed annually, for more than sixty species of fish. 

According to B2RLaw, “the companies will collaborate on developing products using bacteriophage technology to support aquaculture farmers as part of a holistic health strategy. The companies will work in a parallel R&D pipeline on the project.” According to the firm, “the Partnership allows Proteon to grow its product portfolio in aquaculture and expand its presence worldwide. Both Proteon Pharmaceuticals and Skretting predict that the technology will become a valuable component of integrated management strategies on-farm with both feed and water applications under investigation.”

B2RLaw’s team included Partner George Havaris and Counsels Paulina Wyrostek and Malwina Niczke-Chmura.

B2RLaw did not reply to our inquiry on the matter.

Our Latest Issue